Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy

BACKGROUND: We aimed to assess the impact of genomic human leukocyte antigen (HLA)-I/II homozygosity on the survival benefit of patients with unresectable locally advanced, metastatic non-small lung cancer treated by single-agent programmed cell death protein-1/programmed death ligand 1 (PD1/PDL1) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Abed, Afaf, Calapre, Leslie, Lo, Johnny, Correia, Suzana, Bowyer, Samantha, Chopra, Abha, Watson, Mark, Khattak, Muhammad Adnan, Millward, Michael, Gray, Elin Solomonovna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684824/
https://www.ncbi.nlm.nih.gov/pubmed/33229510
http://dx.doi.org/10.1136/jitc-2020-001620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684824/
https://www.ncbi.nlm.nih.gov/pubmed/33229510
http://dx.doi.org/10.1136/jitc-2020-001620

Ejemplares similares